Adaptive Biotechnologies posts Q3 2026 profit with 44% growth in MRD revenue, raising full-year outlook.

Adaptive Biotechnologies reported profitability in Q3 2026 with adjusted EBITDA of $14.3 million and free cash flow of $7.7 million, driven by a 44% increase in core Minimal Residual Disease (MRD) revenue. The company generated $83.9 million in revenue, despite a 11% overall decline due to non-recurring Genentech agreement revenue last year. New clinical guidelines and a definition of cure for multiple myeloma are expected to boost demand for MRD testing, supporting the company’s raised 2026 MRD revenue guidance to $276-$286 million. Adaptive continues to advance its immune medicine segment and pursue Medicare coverage expansion for MRD testing.

Adaptive Biotechnologies shares are currently trading at USD 27.49 on Pluang, showing a strong 1-day gain of 6.55%. The stock has a market cap of $4.12 billion and a 52-week high of $29.84 as of Nov 05, 2026 04:11 WIB.